Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.

Mol Cancer · 2022 · PMC8951705 · PMID 35337339

Europe PMC DOI

hedged sentences

0.0080

closest p · 0.2× alpha

0.1600

boldest claim

The sentences

highly significantP = 0.008actually significant

A pairwise comparison of PFS between patients with PD-L1 + and PD-L1 − tumors also showed a highly significant difference in PFS outcome ( P = 0.008).

also in 132,142 other papers

did not reach statistical significanceP = 0.16not close (p > 0.1)

Patients with CD8 + tumors had a better PFS than those with CD8 − tumors, although this difference did not reach statistical significance ( P = 0.16).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.